Clinical Trials at John Theurer Cancer Center at Hackensack University Medical Center

As of June 2026, 47 paid clinical trials are recruiting at John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

47 clinical trials at John Theurer Cancer Center at Hackensack University Medical Center

·Clear filters·↓ Download CSV

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

for Hematologic Malignancies

Drug: Nemtabrutinib

11 locations incl. Springdale

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT04728893·Phase 2·Recruiting

Apply to this trial

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

for Carcinoma, Non-Small-Cell Lung

18 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT04165070·Phase 1, Phase 2·Recruiting

Apply to this trial

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

for Carcinoma, Non-Small-Cell Lung

18 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT04165798·Recruiting

Apply to this trial

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

for Myelofibrosis

32 locations incl. Birmingham

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 18+

Code: NCT04176198·Phase 1, Phase 2·Recruiting

Apply to this trial

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

for Advanced Solid Tumor

15 locations incl. Los Angeles

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT04145622·Phase 1, Phase 2·Recruiting

Apply to this trial

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

for Solid Tumors

65 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT03486873·Phase 3·Recruiting

Apply to this trial

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Drug: Mevrometostat

45 locations incl. Tucson

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT03460977·Phase 1·Recruiting

Apply to this trial